A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to Investigate the Safety and Efficacy of SC0062 Capsule in Patients With Chronic Kidney Disease With Albuminuria
Latest Information Update: 27 Feb 2025
At a glance
- Drugs SC-0062 (Primary)
- Indications Diabetic nephropathies; IgA nephropathy; Proteinuria
- Focus Therapeutic Use
- Acronyms 2-SUCCEED
- Sponsors Biocity Biopharmaceutics
Most Recent Events
- 25 Feb 2025 According to BioCity Biopharma media release,study results in the DKD cohort are expected to be published in the second quarter of 2025.
- 25 Feb 2025 Results presented in the BioCity Biopharma Media Release.
- 14 Oct 2024 According to BioCity Biopharma media release, results from the study are expected in the near future